Skip to main content

Preclinical Metabolic & Obesity Deal Benchmarks

Median Upfront
$90M
Range: $33M - $152M
Total Deal Value
$1.1B
Range: $514M - $1.8B
Royalty Rate
6.1% - 12.1%
Tiered up to 16.1%
Dev Milestones
$421M
Range: $192M - $647M

Market Analysis

Preclinical metabolic & obesity licensing deals carry a median total deal value of $1.1B, with upfront payments ranging from $33M to $152M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 8% to upfront and 92% to milestones.

The metabolic & obesity landscape at the preclinical stage is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Development milestones average $421M, regulatory milestones contribute $263M, and commercial milestones reach $368M. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations.

Royalty rates for preclinical metabolic & obesity deals range from 6.1% to 12.1% at the base tier, with high-tier escalation to 16.1%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for preclinical metabolic & obesity deals?
Preclinical metabolic & obesity deals average $90M in upfront payments, ranging from $33M to $152M. The upfront allocation of 8% of total deal value reflects the clinical stage risk profile.
How are preclinical metabolic & obesity deal milestones structured?
Milestones account for approximately 92% of total deal value. Development milestones ($421M) represent the largest component, followed by commercial milestones ($368M) and regulatory milestones ($263M).
What royalty rates are typical for preclinical metabolic & obesity licensing?
Base royalty rates range from 6.1% to 12.1%, with tiered escalation to 10.1%-16.1% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included